Trends in therapeutic monoclonal antibodies of cancer

Bibliography

• REICHERT JM, VALGE-ARCHER VE: Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. (2007) 6:349-356.
   PubMed Web of Science ®Google Scholar
• KÖHLER G, MILSTEIN C: Continuous culture of fused cells secreting antibody of predefined specifity. Nature (1975) 256(5517):495-497.
   PubMed Web of Science ®Google Scholar
• KHAZAELI MB, CONRY RM, LOBUGLIO AF: Human immune response to monoclonal antibodies. J. Immunother. Emphasis Tumor Immunol. (1994) 15(1):42-52.
   PubMed Web of Science ®Google Scholar
• MURRAY NA, ROBERTS IA: Haemolytic disease of the newborn. Arch. Dis. Child Fetal Neonatal Ed. (2007) 92(2):F83-F88.
   PubMed Web of Science ®Google Scholar
• OSBOURN J, JERMUTUS L, DUNCAN A: Current methods for the generation of human antibodies for the treatment of autoimmune disease. Drug Discov. Today (2003) 8:845-851.
   PubMed Web of Science ®Google Scholar
• KRAUSS J: Recombinant antibodies for the diagnosis and treatment of cancer. Mol. Biotechnol. (2003) 25:1-17.
   PubMedGoogle Scholar
• DASS S, VITAL EM, EMERY P: Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin. Pharmacother. (2006) 7(18):2559-2570.
   PubMed Web of Science ®Google Scholar
• ZANGEMEISTER-WITTKE U: Antibodies for targeted cancer therapy – technical aspects and clinical perspectives. Pathobiology (2005) 72:279-286.
   PubMedGoogle Scholar
• KIPRIYANOV SM, LE GALL F: Generation and production of engineered antibodies. Mol. Biotechnol. (2004) 26:39-60.
   PubMed Web of Science ®Google Scholar
• BERGER M, SHANKAR V, VAFAI A: Therapeutic applications of monoclonal antibodies. Am. J. Med. Sci. (2002) 324:14-30.
   PubMed Web of Science ®Google Scholar
• KIM SJ, PARK Y, HONG HJ: Antibody engineering for the development of therapeutic antibodies. Mol. Cells (2005) 20(1):17-29.
   PubMed Web of Science ®Google Scholar
• BRUGGEMANN M, TAUSSIG MJ: Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. (1997) 8(4):455-458.
   PubMedGoogle Scholar
• MENDEZ MJ, GREEN LL, CORVALAN JR et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. (1997) 15(2):146-156.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DM: Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. (2002) 43:693-713.
   PubMed Web of Science ®Google Scholar
• SHARKEY RM, GOLDENBERG DM: Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. (2005) 46:S115-S127.
   PubMed Web of Science ®Google Scholar
• ECCLES SA: Monoclonal antibodies targeting cancer: ‘magic bullets’ or just the trigger? Breast Cancer Res. (2001) 3:86-90.
   PubMedGoogle Scholar
• RAVETCH JV: Fc receptors. In: Fundamental Immunology (2003).
   Google Scholar
• NIMMERJAHN F, RAVETCH JV: Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. (2007) 19:239-245.
   PubMed Web of Science ®Google Scholar
• DI GAETANO N, CITTERA E, NOTA R et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. (2003) 171:1581-1587.
   PubMedGoogle Scholar
• GELDERMAN KA, TOMLINSON S, ROSS GD, GORTER A: Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. (2004) 25(3):158-164.
   PubMed Web of Science ®Google Scholar
• HUDIS CA: Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med. (2007) 357(1):39-51.
   PubMed Web of Science ®Google Scholar
• DASSONVILLE O, BOZEC A, FISCHEL JL, MILANO G: EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit. Rev. Oncol. Hematol. (2007) 62(1):53-61.
   PubMed Web of Science ®Google Scholar
• JANAS E, PRIEST R, WILDE JI et al.: Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol. (2005) 139:439-446.
   PubMed Web of Science ®Google Scholar
• RABINOVICH GA, GABRILOVICH D, SOTOMAYOR EM: Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. (2007) 25:267-296.
   PubMed Web of Science ®Google Scholar
• BEREK JS, SCHULTES BC, NICODEMUS CF: Biologic and immunologic therapies for ovarian cancer. J. Clin. Oncol. (2003) 21(10 Suppl.):S168-S174.
   Web of Science ®Google Scholar
• GARCIA-HERNANDEZ MDE L, GRAY A, HUBBY B, KAST WM: In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res. (2007) 67(3):1344-1351.
   PubMedGoogle Scholar
• IMAI H, SAIO M, NONAKA K et al.: Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci. (2007) 98(3):416-423.
   PubMed Web of Science ®Google Scholar
• TAKEDA K, OKUMURA K, SMYTH MJ: Combination antibody-based cancer immunotherapy. Cancer Sci. (2007) (In Press).
   Google Scholar
• MELERO I, HERVAS-STUBBS S, GLENNIE M, PARDOLL DM, CHEN L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer (2007) 7:95-106.
   PubMed Web of Science ®Google Scholar
• MILLER RA, MALONEY DG, WARNKE R, LEVY R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. (1982) 306:517-522.
   PubMed Web of Science ®Google Scholar
• GRILLO-LÓPEZ AJ, HEDRICK E, RASHFORD M, BENYUNES M: Rituximab: ongoing and future clinical development. Semin. Oncol. (2002) 29(1 Suppl. 2):105-112.
   PubMed Web of Science ®Google Scholar
• COIFFIER B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin. Oncol. (2002) 29(1 Suppl. 2):30-35.
   PubMed Web of Science ®Google Scholar
• GRILLO-LÓPEZ AJ: AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev. Anticancer Ther. (2002) 2(3):23-29.
   PubMedGoogle Scholar
• LUNDIN J, OSTERBORG A, BRITTINGER G et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. (1998) 16(10):3257-3263.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99(10):3554-3661.
   PubMed Web of Science ®Google Scholar
• FADERL S, THOMAS DA, O'BRIEN S et al.: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood (2003) 101(9):3413-3415.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-ILIZALITURRI FJ, BIR AS, BROMBOS D, CZUCZMAN MS: Acquirement of resistance to rituximab is associated with upregulation of CD52 antigen: the role of targeting CD52 antigen using alemtuzumab (CAMPATH 1-H) in rituximab-resistant non-Hodgkins lymphoma (NHL) cell lines. Blood (2003) 102:A2379.
   PubMedGoogle Scholar
• PAWSON R, DYER MJ, BARGE R et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol. (1997) 15(7):2667-2672.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AL, CHEN FM, TAYLOR CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res. (1988) 48:5842-5848.
   PubMed Web of Science ®Google Scholar
• KHAWLI L, HU P, EPSTEIN A: Multiple uses of tumour necrosis therapy (TNT) for the treatment and image of solid tumours: preclinical considerations and progress. Update Cancer Ther. (2006) 1:33-47.
   Google Scholar
• CHEN S, YU L, JIANG C et al.: Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J. Clin. Oncol. (2005) 23(7):1538.
   PubMed Web of Science ®Google Scholar
• YU L, JU DW, CHEN W et al.: 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother. Radiopharmaceut. (2006) 21(1):5-14.
   PubMedGoogle Scholar
• MURO K, DAS S, RAIZER JJ: Convection-enhanced and local delivery of targeted cytotoxin in the treatment of malignant glimas. Technol. Cancer Res. Treat. (2006) 5(3):201-213.
   PubMed Web of Science ®Google Scholar
• LIU J, ZHAO Q, ZHAO B et al.: A new format of single chain tri-specific antibody with diminished molecular size efficiently induces ovarian tumor cell killing. Biotechnol. Lett. (2005) 27(22):1821-1827.
   PubMedGoogle Scholar
• SCOTT AM, WISEMAN G, WELT S et al.: A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin. Cancer Res. (2003) 9:1639-1647.
   PubMed Web of Science ®Google Scholar
• REARDON DA, ZALUTSKY MR, BIGNER DD: Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. (2007) 7(5):675-687.
   PubMed Web of Science ®Google Scholar
• BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3:401-410.
   PubMed Web of Science ®Google Scholar
• SANDLER A, GRAY R, PERRY MC et al.: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N. Engl. J. Med. (2006) 355:2542-2550.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• SLEDGE GW Jr: Breast cancer in the clinic: treatment past, treatment future. J. Mammary Gland Biol. Neoplasia (2001) 6:487-495.
   PubMedGoogle Scholar
• DEVORE R, FEHRENBACHER L, HERBST R: A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vasuclar endothelial cell growth factor) plus carboplatin/paclitaxel (C/P) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. (2000) 19:A485.
   Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
   PubMed Web of Science ®Google Scholar
• COCHLOVIUS B, KIPRIYANOV SM, STASSAR MJ et al.: Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res. (2000) 60:4336-4341.
   PubMed Web of Science ®Google Scholar
• WATTS TH: TNF/TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol. (2005) 23:23-68.
   PubMed Web of Science ®Google Scholar
• MELERO I, SHUFORD WW, NEWBY SA et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. (1997) 3:682-685.
   PubMed Web of Science ®Google Scholar
• WILCOX RA, TAMADA K, FLIES DB et al.: Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood (2004) 103:177-184.
   PubMed Web of Science ®Google Scholar
• TEFT WA, KIRCHHOF MG, MADRENAS J: A molecular perspective of CTLA-4 function. Ann. Rev. Immunol. (2006) 24:65-97.
   PubMed Web of Science ®Google Scholar
• KORMAN AJ, PEGGS KS, ALLISON JP: Checkpoint blockade in cancer immunotherapy. Adv. Immunol. (2006) 90:297-339.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707-712.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
   PubMed Web of Science ®Google Scholar
• ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1673-1684.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
   PubMed Web of Science ®Google Scholar
• LANGER CJ, STEPHENSON P, THOR A et al.: Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on eastern cooperative oncology group study 2598. J. Clin. Oncol. (2004) 22(7):1180-1187.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. (2003) 22:252.
   Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMCC225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc. Am. Soc. Clin. Oncol. (2001) 20:7.
   Web of Science ®Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr, NEEDLE MN, KOPIT J, MAYER RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1208.
   PubMed Web of Science ®Google Scholar
• LENZ HJ, MAYER RJ, GOLD PJ et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. (2004) 23:3510.
   Google Scholar
• GOVINDAN R: Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. (2004) 10:S4241-S4244.
   Web of Science ®Google Scholar
• BODE U, BUCHEN S, JANSSEN G et al.: Results of a Phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J. Clin. Oncol. (2006) 24(18S):1552.
   Google Scholar
• ALLAN DG: Nimotumab: evidence of clinical benefit without rash. Oncologist (2005) 10:760-761.
   PubMedGoogle Scholar
• CHRIS EASLEY PK: Panitumumab. Nat. Drug Discov. (2006) 5:987-988.
   PubMedGoogle Scholar